Merck Q2 2026 sales rise 5% to $16.6B; 2026 EPS guidance cut to $2.66-2.76 on acquisition charges

Merck reported second-quarter 2026 sales of $16.61 billion, up 5% (4% excluding FX), with Keytruda and Keytruda Qlex at $8.37 billion. The quarter was a loss of $(0.13) per share non-GAAP and $(0.54) GAAP because of a $5.7 billion R&D charge for the Terns acquisition. The company raised 2026 sales guidance to $66.3-67.3 billion but cut non-GAAP EPS guidance to $2.66-2.76 from $5.04-5.16, including one-time acquisition charges.

• Sales $16,607M, up 5%; Winrevair $588M (+75%); Gardasil $1,169M (+4%); Animal Health $1,775M (+8%)
• Non-GAAP EPS $(0.13); GAAP EPS $(0.54)
• Terns charge: $5.7B recorded in R&D, $2.31 per share
• 2026 sales guidance $66.3-67.3B, up from $65.8-67.0B
• 2026 non-GAAP EPS guidance $2.66-2.76, down from $5.04-5.16; includes a $3.62 per share Cidara charge

SEC filing 8-K · accession 0001104659-26-090045 · sec.gov ↗